Humanized FcγRIIB-specific antibodies and methods of use thereof
US8216579B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 21, 2010 |
| Grant date | Jul 10, 2012 |
| Priority date | — |
| Expiry date | May 21, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.